

FIRST REGULAR SESSION

SENATE BILL NO. 354

96TH GENERAL ASSEMBLY

INTRODUCED BY SENATOR SCHAAF.

Read 1st time February 28, 2011, and ordered printed.

TERRY L. SPIELER, Secretary.

1781S.011

AN ACT

To repeal section 195.017, RSMo, and to enact in lieu thereof one new section relating to controlled substances, with an existing penalty provision.

Be it enacted by the General Assembly of the State of Missouri, as follows:

Section A. Section 195.017, RSMo, is repealed and one new section
2 enacted in lieu thereof, to be known as section 195.017, to read as follows:

195.017. 1. The department of health and senior services shall place a
2 substance in Schedule I if it finds that the substance:

3 (1) Has high potential for abuse; and

4 (2) Has no accepted medical use in treatment in the United States or
5 lacks accepted safety for use in treatment under medical supervision.

6 2. Schedule I:

7 (1) The controlled substances listed in this subsection are included in
8 Schedule I;

9 (2) Any of the following opiates, including their isomers, esters, ethers,
10 salts, and salts of isomers, esters, and ethers, unless specifically excepted,
11 whenever the existence of these isomers, esters, ethers and salts is possible
12 within the specific chemical designation:

13 (a) Acetyl-alpha-methylfentanyl;

14 (b) Acetylmethadol;

15 (c) Allylprodine;

16 (d) Alphacetylmethadol;

17 (e) Alphameprodine;

18 (f) Alphamethadol;

19 (g) Alpha-methylfentanyl;

EXPLANATION—Matter enclosed in bold-faced brackets [thus] in this bill is not enacted and is intended to be omitted in the law.

- 20 (h) Alpha-methylthiofentanyl;
21 (i) Benzethidine;
22 (j) Betacetylmethadol;
23 (k) Beta-hydroxyfentanyl;
24 (l) Beta-hydroxy-3-methylfentanyl;
25 (m) Betameprodine;
26 (n) Betamethadol;
27 (o) Betaprodine;
28 (p) Clonitazene;
29 (q) Dextromoramide;
30 (r) Diampromide;
31 (s) Diethylthiambutene;
32 (t) Difenoxin;
33 (u) Dimenoxadol;
34 (v) Dimepheptanol;
35 (w) Dimethylthiambutene;
36 (x) Dioxaphetyl butyrate;
37 (y) Dipipanone;
38 (z) Ethylmethylthiambutene;
39 (aa) Etonitazene;
40 (bb) Etoxidine;
41 (cc) Furethidine;
42 (dd) Hydroxypethidine;
43 (ee) Ketobemidone;
44 (ff) Levomoramide;
45 (gg) Levophenacetylmorphan;
46 (hh) 3-Methylfentanyl;
47 (ii) 3-Methylthiofentanyl;
48 (jj) Morpheridine;
49 (kk) MPPP;
50 (ll) Noracetylmethadol;
51 (mm) Norlevorphanol;
52 (nn) Normethadone;
53 (oo) Norpipanone;
54 (pp) Para-fluorofentanyl;
55 (qq) PEPAP;

- 56 (rr) Phenadoxone;
- 57 (ss) Phenampromide;
- 58 (tt) Phenomorphan;
- 59 (uu) Phenoperidine;
- 60 (vv) Piritramide;
- 61 (ww) Proheptazine;
- 62 (xx) Properidine;
- 63 (yy) Propiram;
- 64 (zz) Racemoramide;
- 65 (aaa) Thiofentanyl;
- 66 (bbb) Tilidine;
- 67 (ccc) Trimeperidine;
- 68 (3) Any of the following opium derivatives, their salts, isomers and salts
69 of isomers unless specifically excepted, whenever the existence of these salts,
70 isomers and salts of isomers is possible within the specific chemical designation:
- 71 (a) Acetorphine;
- 72 (b) Acetyldihydrocodeine;
- 73 (c) Benzylmorphine;
- 74 (d) Codeine methylbromide;
- 75 (e) Codeine-N-Oxide;
- 76 (f) Cyprenorphine;
- 77 (g) Desomorphine;
- 78 (h) Dihydromorphine;
- 79 (i) Drotebanol;
- 80 (j) Etorphine (except hydrochloride salt);
- 81 (k) Heroin;
- 82 (l) Hydromorphenol;
- 83 (m) Methyldesorphine;
- 84 (n) Methyldihydromorphine;
- 85 (o) Morphine methylbromide;
- 86 (p) Morphine methylsulfonate;
- 87 (q) Morphine-N-Oxide;
- 88 (r) Myrophine;
- 89 (s) Nicocodeine;
- 90 (t) Nicomorphine;
- 91 (u) Normorphine;

- 92 (v) Pholcodine;
- 93 (w) Thebacon;
- 94 (4) Any material, compound, mixture or preparation which contains any
95 quantity of the following hallucinogenic substances, their salts, isomers and salts
96 of isomers, unless specifically excepted, whenever the existence of these salts,
97 isomers, and salts of isomers is possible within the specific chemical designation:
- 98 (a) 4-bromo-2, 5-dimethoxyamphetamine;
- 99 (b) 4-bromo-2, 5-dimethoxyphenethylamine;
- 100 (c) 2,5-dimethoxyamphetamine;
- 101 (d) 2,5-dimethoxy-4-ethylamphetamine;
- 102 (e) 2,5-dimethoxy-4-(n)-propylthiophenethylamine;
- 103 (f) 4-methoxyamphetamine;
- 104 (g) 5-methoxy-3,4-methylenedioxyamphetamine;
- 105 (h) 4-methyl-2, 5-dimethoxyamphetamine;
- 106 (i) 3,4-methylenedioxyamphetamine;
- 107 (j) 3,4-methylenedioxymethamphetamine;
- 108 (k) 3,4-methylenedioxy-N-ethylamphetamine;
- 109 (l) N-hydroxy-3, 4-methylenedioxyamphetamine;
- 110 (m) 3,4,5-trimethoxyamphetamine;
- 111 (n) 5-MeO-DMT or 5-methoxy-N,N-dimethyltryptamine, its isomers, salts,
112 and salts of isomers;
- 113 (o) Alpha-ethyltryptamine;
- 114 (p) Alpha-methyltryptamine;
- 115 (q) Bufotenine;
- 116 (r) D e x a n a b i n o l ,
117 (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10
118 a-tetrahydrobenzo[c]chromen-1-ol;
- 119 (s) Diethyltryptamine;
- 120 (t) Dimethyltryptamine;
- 121 (u) 5-methoxy-N,N-diisopropyltryptamine;
- 122 (v) Ibogaine;
- 123 (w) Indole, or 1-butyl-3(1-naphthoyl)indole;
- 124 (x) Indole, or 1-pentyl-3(1-naphthoyl)indole;
- 125 (y) Lysergic acid diethylamide;
- 126 (z) Marijuana or marihuana;
- 127 (aa) Mescaline;

- 128 (bb) Parahehexyl;
- 129 (cc) Peyote, to include all parts of the plant presently classified botanically
130 as *Lophophora Williamsii* Lemaire, whether growing or not; the seeds thereof; any
131 extract from any part of such plant; and every compound, manufacture, salt,
132 derivative, mixture or preparation of the plant, its seed or extracts;
- 133 (dd) Phenol, CP 47, 497 & homologues, or
134 2-[(1R,3S)-3-hydroxycyclohexyl]-5-(2-methyloctan-2-yl)phenol, where side chain
135 n=5, and homologues where side chain n=4,6, or 7;
- 136 (ee) N-ethyl-3-piperidyl benzilate;
- 137 (ff) N-methyl-3-piperidyl benzilate;
- 138 (gg) Psilocybin;
- 139 (hh) Psilocyn;
- 140 (ii) Tetrahydrocannabinols naturally contained in a plant of the genus
141 *Cannabis* (cannabis plant), as well as synthetic equivalents of the substances
142 contained in the cannabis plant, or in the resinous extractives of such plant, or
143 synthetic substances, derivatives, and their isomers with similar chemical
144 structure and pharmacological activity to those substances contained in the plant,
145 such as the following:
- 146 a. 1 cis or trans tetrahydrocannabinol, and their optical isomers;
- 147 b. 6 cis or trans tetrahydrocannabinol, and their optical isomers;
- 148 c. 3,4 cis or trans tetrahydrocannabinol, and their optical isomers;
- 149 d. Any compounds of these structures, regardless of numerical designation
150 of atomic positions covered;
- 151 (jj) Ethylamine analog of phencyclidine;
- 152 (kk) Pyrrolidine analog of phencyclidine;
- 153 (ll) Thiophene analog of phencyclidine;
- 154 (mm) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine;
- 155 (nn) *Salvia divinorum*;
- 156 (oo) Salvinorin A;
- 157 (5) Any material, compound, mixture or preparation containing any
158 quantity of the following substances having a depressant effect on the central
159 nervous system, including their salts, isomers and salts of isomers whenever the
160 existence of these salts, isomers and salts of isomers is possible within the
161 specific chemical designation:
- 162 (a) Gamma-hydroxybutyric acid;
- 163 (b) Mecloqualone;

164 (c) Methaqualone;

165 (6) Any material, compound, mixture or preparation containing any
166 quantity of the following substances having a stimulant effect on the central
167 nervous system, including their salts, isomers and salts of isomers:

168 (a) Aminorex;

169 (b) N-benzylpiperazine;

170 (c) Cathinone;

171 (d) Fenethylamine;

172 (e) Methcathinone;

173 **(f) Methylenedioxypropylone or [(MDPV) (1-(1,3-Benzodioxol-**
174 **5-yl)-2-(1-pyrrolidinyl)-1-pentanone];**

175 **[(f)] (g) (+,-)cis-4-methylaminorex ((+,-)cis-4,5-dihydro-4-methyl-5-pheny**
176 **l-2-oxazoline);**

177 **[(g)] (h) N-ethylamphetamine;**

178 **[(h)] (i) N,N-dimethylamphetamine;**

179 (7) A temporary listing of substances subject to emergency scheduling
180 under federal law shall include any material, compound, mixture or preparation
181 which contains any quantity of the following substances:

182 (a) N-(1-benzyl-4-piperidyl)-N phenylpropanamide (benzylfentanyl), its
183 optical isomers, salts and salts of isomers;

184 (b) N-(1-(2-thienyl)methyl-4-piperidyl)-N-phenylpropanamide
185 (thenylfentanyl), its optical isomers, salts and salts of isomers;

186 (8) Khat, to include all parts of the plant presently classified botanically
187 as *catha edulis*, whether growing or not; the seeds thereof; any extract from any
188 part of such plant; and every compound, manufacture, salt, derivative, mixture,
189 or preparation of the plant, its seed or extracts.

190 3. The department of health and senior services shall place a substance
191 in Schedule II if it finds that:

192 (1) The substance has high potential for abuse;

193 (2) The substance has currently accepted medical use in treatment in the
194 United States, or currently accepted medical use with severe restrictions; and

195 (3) The abuse of the substance may lead to severe psychic or physical
196 dependence.

197 4. The controlled substances listed in this subsection are included in
198 Schedule II:

199 (1) Any of the following substances whether produced directly or indirectly

200 by extraction from substances of vegetable origin, or independently by means of
201 chemical synthesis, or by combination of extraction and chemical synthesis:

202 (a) Opium and opiate and any salt, compound, derivative or preparation
203 of opium or opiate, excluding apomorphine, thebaine-derived butorphanol,
204 dextrorphan, nalbuphine, nalmefene, naloxone and naltrexone, and their
205 respective salts but including the following:

- 206 a. Raw opium;
- 207 b. Opium extracts;
- 208 c. Opium fluid;
- 209 d. Powdered opium;
- 210 e. Granulated opium;
- 211 f. Tincture of opium;
- 212 g. Codeine;
- 213 h. Ethylmorphine;
- 214 i. Etorphine hydrochloride;
- 215 j. Hydrocodone;
- 216 k. Hydromorphone;
- 217 l. Metopon;
- 218 m. Morphine;
- 219 n. Oxycodone;
- 220 o. Oxymorphone;
- 221 p. Thebaine;

222 (b) Any salt, compound, derivative, or preparation thereof which is
223 chemically equivalent or identical with any of the substances referred to in this
224 subdivision, but not including the isoquinoline alkaloids of opium;

225 (c) Opium poppy and poppy straw;

226 (d) Coca leaves and any salt, compound, derivative, or preparation of coca
227 leaves, and any salt, compound, derivative, or preparation thereof which is
228 chemically equivalent or identical with any of these substances, but not including
229 decocainized coca leaves or extractions which do not contain cocaine or ecgonine;

230 (e) Concentrate of poppy straw (the crude extract of poppy straw in either
231 liquid, solid or powder form which contains the phenanthrene alkaloids of the
232 opium poppy);

233 (2) Any of the following opiates, including their isomers, esters, ethers,
234 salts, and salts of isomers, whenever the existence of these isomers, esters, ethers
235 and salts is possible within the specific chemical designation, dextrorphan and

236 levopropoxyphene excepted:

- 237 (a) Alfentanil;
- 238 (b) Alphaprodine;
- 239 (c) Anileridine;
- 240 (d) Bezitramide;
- 241 (e) Bulk dextropropoxyphene;
- 242 (f) Carfentanil;
- 243 (g) Dihydrocodeine;
- 244 (h) Diphenoxylate;
- 245 (i) Fentanyl;
- 246 (j) Isomethadone;
- 247 (k) Levo-alphaacetylmethadol;
- 248 (l) Levomethorphan;
- 249 (m) Levorphanol;
- 250 (n) Metazocine;
- 251 (o) Methadone;
- 252 (p) Meperidine;
- 253 (q) Methadone-Intermediate, 4-cyano-2-dimethylamino-4,
254 4-diphenylbutane;
- 255 (r) Moramide-Intermediate, 2-methyl-3-morpholino-1,
256 1-diphenylpropane--carboxylic acid;
- 257 (s) Pethidine (meperidine);
- 258 (t) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
- 259 (u) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;
- 260 (v) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic
261 acid;
- 262 (w) Phenazocine;
- 263 (x) Piminodine;
- 264 (y) Racemethorphan;
- 265 (z) Racemorphan;
- 266 (aa) Remifentanil;
- 267 (bb) Sufentanil;
- 268 (cc) Tapentadol;
- 269 (3) Any material, compound, mixture, or preparation which contains any
270 quantity of the following substances having a stimulant effect on the central
271 nervous system:

272 (a) Amphetamine, its salts, optical isomers, and salts of its optical
273 isomers;

274 (b) Lisdexamfetamine, its salts, isomers, and salts of its isomers;

275 (c) Methamphetamine, its salts, isomers, and salts of its isomers;

276 (d) Phenmetrazine and its salts;

277 (e) Methylphenidate;

278 (4) Any material, compound, mixture, or preparation which contains any
279 quantity of the following substances having a depressant effect on the central
280 nervous system, including its salts, isomers, and salts of isomers whenever the
281 existence of those salts, isomers, and salts of isomers is possible within the
282 specific chemical designation:

283 (a) Amobarbital;

284 (b) Glutethimide;

285 (c) Pentobarbital;

286 (d) Phencyclidine;

287 (e) Secobarbital;

288 (5) Any material or compound which contains any quantity of nabilone;

289 (6) Any material, compound, mixture, or preparation which contains any
290 quantity of the following substances:

291 (a) Immediate precursor to amphetamine and methamphetamine:
292 Phenylacetone;

293 (b) Immediate precursors to phencyclidine (PCP):

294 a. 1-phenylcyclohexylamine;

295 b. 1-piperidinocyclohexanecarbonitrile (PCC);

296 (7) Any material, compound, mixture, or preparation which contains any
297 quantity of the following alkyl nitrites:

298 (a) Amyl nitrite;

299 (b) Butyl nitrite.

300 5. The department of health and senior services shall place a substance
301 in Schedule III if it finds that:

302 (1) The substance has a potential for abuse less than the substances listed
303 in Schedules I and II;

304 (2) The substance has currently accepted medical use in treatment in the
305 United States; and

306 (3) Abuse of the substance may lead to moderate or low physical
307 dependence or high psychological dependence.

308 6. The controlled substances listed in this subsection are included in
309 Schedule III:

310 (1) Any material, compound, mixture, or preparation which contains any
311 quantity of the following substances having a potential for abuse associated with
312 a stimulant effect on the central nervous system:

- 313 (a) Benzphetamine;
- 314 (b) Chlorphentermine;
- 315 (c) Clortermine;
- 316 (d) Phendimetrazine;

317 (2) Any material, compound, mixture or preparation which contains any
318 quantity or salt of the following substances or salts having a depressant effect on
319 the central nervous system:

320 (a) Any material, compound, mixture or preparation which contains any
321 quantity or salt of the following substances combined with one or more active
322 medicinal ingredients:

- 323 a. Amobarbital;
- 324 b. Secobarbital;
- 325 c. Pentobarbital;

326 (b) Any suppository dosage form containing any quantity or salt of the
327 following:

- 328 a. Amobarbital;
- 329 b. Secobarbital;
- 330 c. Pentobarbital;

331 (c) Any substance which contains any quantity of a derivative of
332 barbituric acid or its salt;

- 333 (d) Chlorhexadol;
- 334 (e) Embutramide;

335 (f) Gamma hydroxybutyric acid and its salts, isomers, and salts of isomers
336 contained in a drug product for which an application has been approved under
337 Section 505 of the federal Food, Drug, and Cosmetic Act;

338 (g) Ketamine, its salts, isomers, and salts of isomers;

339 (h) Lysergic acid;

340 (i) Lysergic acid amide;

341 (j) Methyprylon;

342 (k) Sulfondiethylmethane;

343 (l) Sulfonethylmethane;

- 344 (m) Sulfonylmethane;
- 345 (n) Tiletamine and zolazepam or any salt thereof;
- 346 (3) Nalorphine;
- 347 (4) Any material, compound, mixture, or preparation containing limited
348 quantities of any of the following narcotic drugs or their salts:
- 349 (a) Not more than 1.8 grams of codeine per one hundred milliliters or not
350 more than ninety milligrams per dosage unit, with an equal or greater quantity
351 of an isoquinoline alkaloid of opium;
- 352 (b) Not more than 1.8 grams of codeine per one hundred milliliters or not
353 more than ninety milligrams per dosage unit with one or more active, nonnarcotic
354 ingredients in recognized therapeutic amounts;
- 355 (c) Not more than three hundred milligrams of hydrocodone per one
356 hundred milliliters or not more than fifteen milligrams per dosage unit, with a
357 fourfold or greater quantity of an isoquinoline alkaloid of opium;
- 358 (d) Not more than three hundred milligrams of hydrocodone per one
359 hundred milliliters or not more than fifteen milligrams per dosage unit, with one
360 or more active nonnarcotic ingredients in recognized therapeutic amounts;
- 361 (e) Not more than 1.8 grams of dihydrocodeine per one hundred milliliters
362 or not more than ninety milligrams per dosage unit, with one or more active
363 nonnarcotic ingredients in recognized therapeutic amounts;
- 364 (f) Not more than three hundred milligrams of ethylmorphine per one
365 hundred milliliters or not more than fifteen milligrams per dosage unit, with one
366 or more active, nonnarcotic ingredients in recognized therapeutic amounts;
- 367 (g) Not more than five hundred milligrams of opium per one hundred
368 milliliters or per one hundred grams or not more than twenty-five milligrams per
369 dosage unit, with one or more active nonnarcotic ingredients in recognized
370 therapeutic amounts;
- 371 (h) Not more than fifty milligrams of morphine per one hundred milliliters
372 or per one hundred grams, with one or more active, nonnarcotic ingredients in
373 recognized therapeutic amounts;
- 374 (5) Any material, compound, mixture, or preparation containing any of the
375 following narcotic drugs or their salts, as set forth in subdivision (6) of this
376 subsection; buprenorphine;
- 377 (6) Anabolic steroids. Any drug or hormonal substance, chemically and
378 pharmacologically related to testosterone (other than estrogens, progestins,
379 corticosteroids, and dehydroepiandrosterone) that promotes muscle growth, except

380 an anabolic steroid which is expressly intended for administration through
 381 implants to cattle or other nonhuman species and which has been approved by
 382 the Secretary of Health and Human Services for that administration. If any
 383 person prescribes, dispenses, or distributes such steroid for human use, such
 384 person shall be considered to have prescribed, dispensed, or distributed an
 385 anabolic steroid within the meaning of this [paragraph] **subdivision**. Unless
 386 specifically excepted or unless listed in another schedule, any material,
 387 compound, mixture or preparation containing any quantity of the following
 388 substances, including its salts, esters and ethers:

- 389 (a) 3 β ,17-dihydroxy-5 α -androstane;
 390 (b) 3 α ,17 β -dihydroxy-5 α -androstane;
 391 (c) 5 α -androstan-3,17-dione;
 392 (d) 1-androstenediol (3 β ,17 β -dihydroxy-5 α -androst-1-ene);
 393 (e) 1-androstenediol (3 α ,17 β -dihydroxy-5 α -androst-1-ene);
 394 (f) 4-androstenediol (3 β ,17 β -dihydroxy-androst-4-ene);
 395 (g) 5-androstenediol (3 β ,17 β -dihydroxy-androst-5-ene);
 396 (h) 1-androstenedione ([5 α]-androst-1-en-3,17-dione);
 397 (i) 4-androstenedione (androst-4-en-3,17-dione);
 398 (j) 5-androstenedione (androst-5-en-3,17-dione);
 399 (k) Bolasterone (7 α , 17 α -dimethyl-17 β -hydroxyandrost-4-en-3-one);
 400 (l) Boldenone (17 β -hydroxyandrost-1,4,-diene-3-one);
 401 (m) Boldione;
 402 (n) Calusterone (7 β , 17 α -dimethyl-17 β -hydroxyandrost-4-en-3-one);
 403 (o) Clostebol (4-chloro-17 β -hydroxyandrost-4-en-3-one);
 404 (p) D e h y d r o c h l o r o m e t h y l t e s t o s t e r o n e
 405 (4-chloro-17 β -hydroxy-17 α -methyl-androst-1,4-dien-3-one);
 406 (q) Desoxymethyltestosterone;
 407 (r) Δ 1 - d i h y d r o t e s t o s t e r o n e (a . k . a .
 408 '1-testosterone')(17 β -hydroxy-5 α -androst-1-en-3-one);
 409 (s) 4-dihydrotestosterone (17 β -hydroxy-androstan-3-one);
 410 (t) Drostanolone (17 β -hydroxy-2 α -methyl-5 α -androstan-3-one);
 411 (u) Ethylestrenol (17 α -ethyl-17 β -hydroxyestr-4-ene);
 412 (v) F l u o x y m e s t e r o n e
 413 (9-fluoro-17 α -methyl-11 β ,17 β -dihydroxyandrost-4-en-3-one);
 414 (w) F o r m e b o l o n e
 415 (2-formyl-17 α -methyl-11 α ,17 β -dihydroxyandrost-1,4-dien-3-one);

- 416 (x) Furazabol (17 α -methyl-17 β -hydroxyandrostando[2,3-c]-furazan);
- 417 (y) 13 β -ethyl-17 β -hydroxygon-4-en-3-one;
- 418 (z) 4-hydroxytestosterone (4,17 β -dihydroxy-androst-4-en-3-one);
- 419 (aa) 4-hydroxy-19-nortestosterone (4,17 β -dihydroxy-estr-4-en-3-one);
- 420 (bb) Mestanolone (17 α -methyl-17 β -hydroxy-5-androstan-3-one);
- 421 (cc) Mesterolone (1 α -methyl-17 β -hydroxy-[5 α]-androstan-3-one);
- 422 (dd) Methandienone (17 α -methyl-17 β -hydroxyandrost-1,4-dien-3-one);
- 423 (ee) Methandriol (17 α -methyl-3 β ,17 β -dihydroxyandrost-5-ene);
- 424 (ff) Methenolone (1-methyl-17 β -hydroxy-5 α -androst-1-en-3-one);
- 425 (gg) 17 α -methyl-3 β ,17 β -dihydroxy-5 α -androstande);
- 426 (hh) 17 α -methyl-3 α ,17 β -dihydroxy-5 α -androstande);
- 427 (ii) 17 α -methyl-3 β ,17 β -dihydroxyandrost-4-ene;
- 428 (j j) 1 7 α - m e t h y l - 4 - h y d r o x y n a n d r o l o n e
- 429 (17 α -methyl-4-hydroxy-17 β -hydroxyestr-4-en-3-one);
- 430 (kk) Methyldienolone (17 α -methyl-17 β -hydroxyestra-4,9(10)-dien-3-one);
- 431 (ll) Methyltrienolone (17 α -methyl-17 β -hydroxyestra-4,9-11-trien-3-one);
- 432 (mm) Methyltestosterone (17 α -methyl-17 β -hydroxyandrost-4-en-3-one);
- 433 (nn) Mibolerone (7 α ,17 α -dimethyl-17 β -hydroxyestr-4-en-3-one);
- 434 (o o) 1 7 α - m e t h y l - Δ 1 - d i h y d r o t e s t o s t e r o n e
- 435 (1 7 β β - h y d r o x y - 1 7 α - m e t h y l - 5 α - a n d r o s t - 1 - e n - 3 - o n e)
- 436 (a.k.a. '17- α -methyl-1-testosterone');
- 437 (pp) Nandrolone (17 β -hydroxyestr-4-ene-3-one);
- 438 (qq) 19-nor-4-androstenediol (3 β ,17 β -dihydroxyestr-4-ene);
- 439 (rr) 19-nor-4-androstenediol (3 α ,17 β -dihydroxyestr-4-ene);
- 440 (ss) 19-nor-4,9(10)-androstadienedione;
- 441 (tt) 19-nor-5-androstenediol (3 β ,17 β -dihydroxyestr-5-ene);
- 442 (uu) 19-nor-5-androstenediol (3 α ,17 β -dihydroxyestr-5-ene);
- 443 (vv) 19-nor-4-androstenedione (estr-4-en-3,17-dione);
- 444 (ww) 19-nor-5-androstenedione (estr-5-en-3,17-dione);
- 445 (xx) Norbolethone (13 β ,17 α -diethyl-17 β -hydroxygon-4-en-3-one);
- 446 (yy) Norclostebol (4-chloro-17 β -hydroxyestr-4-en-3-one);
- 447 (zz) Norethandrolone (17 α -ethyl-17 β -hydroxyestr-4-en-3-one);
- 448 (aaa) Normethandrolone (17 α -methyl-17 β -hydroxyestr-4-en-3-one);
- 449 (bbb) Oxandrolone (17 α -methyl-17 β -hydroxy-2-oxa-[5 α]-androstan-3-one);
- 450 (ccc) Oxymesterone (17 α -methyl-4,17 β -dihydroxyandrost-4-en-3-one);
- 451 (d d d) O x y m e t h a l o n e

452 (17 α -methyl-2-hydroxymethylene-17 β -hydroxy-[5 α]-androstan-3-one);
453 (e e e) S t a n o z o l o l
454 (17 α -methyl-17 β -hydroxy-[5 α]-androst-2-eno[3,2-c]-pyrazole);
455 (fff) Stenbolone (17 β -hydroxy-2-methyl-[5 α]-androst-1-en-3-one);
456 (ggg) Testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic
457 acid lactone);
458 (hhh) Testosterone (17 β -hydroxyandrost-4-en-3-one);
459 (iii) Tetrahydrogestrinone (13 β ,17 α -diethyl-17 β -hydroxygon-4,9,11-trien-3-one);
460 (jjj) Trenbolone (17 β -hydroxyestr-4,9,11-trien-3-one);
461 (kkk) Any salt, ester, or ether of a drug or substance described or listed
462 in this subdivision, except an anabolic steroid which is expressly intended for
463 administration through implants to cattle or other nonhuman species and which
464 has been approved by the Secretary of Health and Human Services for that
465 administration;

466 (7) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin
467 capsule in a United States Food and Drug Administration approved drug product;

468 (8) The department of health and senior services may except by rule any
469 compound, mixture, or preparation containing any stimulant or depressant
470 substance listed in subdivisions (1) and (2) of this subsection from the application
471 of all or any part of sections 195.010 to 195.320 if the compound, mixture, or
472 preparation contains one or more active medicinal ingredients not having a
473 stimulant or depressant effect on the central nervous system, and if the
474 admixtures are included therein in combinations, quantity, proportion, or
475 concentration that vitiate the potential for abuse of the substances which have
476 a stimulant or depressant effect on the central nervous system.

477 7. The department of health and senior services shall place a substance
478 in Schedule IV if it finds that:

479 (1) The substance has a low potential for abuse relative to substances in
480 Schedule III;

481 (2) The substance has currently accepted medical use in treatment in the
482 United States; and

483 (3) Abuse of the substance may lead to limited physical dependence or
484 psychological dependence relative to the substances in Schedule III.

485 8. The controlled substances listed in this subsection are included in
486 Schedule IV:

487 (1) Any material, compound, mixture, or preparation containing any of the

488 following narcotic drugs or their salts calculated as the free anhydrous base or
489 alkaloid, in limited quantities as set forth below:

490 (a) Not more than one milligram of difenoxin and not less than twenty-five
491 micrograms of atropine sulfate per dosage unit;

492 (b) Dextropropoxyphene (alpha-(+)-4-dimethylamino-1, 2-diphenyl-3-methyl-2-
493 propionoxybutane);

494 (c) Any of the following limited quantities of narcotic drugs or their salts,
495 which shall include one or more nonnarcotic active medicinal ingredients in
496 sufficient proportion to confer upon the compound, mixture or preparation
497 valuable medicinal qualities other than those possessed by the narcotic drug
498 alone:

499 a. Not more than two hundred milligrams of codeine per one hundred
500 milliliters or per one hundred grams;

501 b. Not more than one hundred milligrams of dihydrocodeine per one
502 hundred milliliters or per one hundred grams;

503 c. Not more than one hundred milligrams of ethylmorphine per one
504 hundred milliliters or per one hundred grams;

505 (2) Any material, compound, mixture or preparation containing any
506 quantity of the following substances, including their salts, isomers, and salts of
507 isomers whenever the existence of those salts, isomers, and salts of isomers is
508 possible within the specific chemical designation:

509 (a) Alprazolam;

510 (b) Barbitol;

511 (c) Bromazepam;

512 (d) Camazepam;

513 (e) Chloral betaine;

514 (f) Chloral hydrate;

515 (g) Chlordiazepoxide;

516 (h) Clobazam;

517 (i) Clonazepam;

518 (j) Clorazepate;

519 (k) Clotiazepam;

520 (l) Cloxazolam;

521 (m) Delorazepam;

522 (n) Diazepam;

523 (o) Dichloralphenazone;

- 524 (p) Estazolam;
- 525 (q) Ethchlorvynol;
- 526 (r) Ethinamate;
- 527 (s) Ethyl loflazepate;
- 528 (t) Fludiazepam;
- 529 (u) Flunitrazepam;
- 530 (v) Flurazepam;
- 531 (w) Fospropofol;
- 532 (x) Halazepam;
- 533 (y) Haloxazolam;
- 534 (z) Ketazolam;
- 535 (aa) Loprazolam;
- 536 (bb) Lorazepam;
- 537 (cc) Lormetazepam;
- 538 (dd) Mebutamate;
- 539 (ee) Medazepam;
- 540 (ff) Meprobamate;
- 541 (gg) Methohexital;
- 542 (hh) Methylphenobarbital (mephobarbital);
- 543 (ii) Midazolam;
- 544 (jj) Nimetazepam;
- 545 (kk) Nitrazepam;
- 546 (ll) Nordiazepam;
- 547 (mm) Oxazepam;
- 548 (nn) Oxazolam;
- 549 (oo) Paraldehyde;
- 550 (pp) Petrichloral;
- 551 (qq) Phenobarbital;
- 552 (rr) Pinazepam;
- 553 (ss) Prazepam;
- 554 (tt) Quazepam;
- 555 (uu) Temazepam;
- 556 (vv) Tetrazepam;
- 557 (ww) Triazolam;
- 558 (xx) Zaleplon;
- 559 (yy) Zolpidem;

560 (zz) Zopiclone;

561 (3) Any material, compound, mixture, or preparation which contains any
562 quantity of the following substance including its salts, isomers and salts of
563 isomers whenever the existence of such salts, isomers and salts of isomers is
564 possible: fenfluramine;

565 (4) Any material, compound, mixture or preparation containing any
566 quantity of the following substances having a stimulant effect on the central
567 nervous system, including their salts, isomers and salts of isomers:

568 (a) Cathine ((+)-norpseudoephedrine);

569 (b) Diethylpropion;

570 (c) Fencamfamin;

571 (d) Fenproporex;

572 (e) Mazindol;

573 (f) Mefenorex;

574 (g) Modafinil;

575 (h) Pemoline, including organometallic complexes and chelates thereof;

576 (i) Phentermine;

577 (j) Pipradrol;

578 (k) Sibutramine;

579 (l) SPA ((-)-1-dimethylamino-1,2-diphenylethane);

580 (5) Any material, compound, mixture or preparation containing any
581 quantity of the following substance, including its salts:

582 (a) Butorphanol;

583 (b) Pentazocine;

584 (6) Ephedrine, its salts, optical isomers and salts of optical isomers, when
585 the substance is the only active medicinal ingredient;

586 (7) The department of health and senior services may except by rule any
587 compound, mixture, or preparation containing any depressant substance listed in
588 subdivision (1) of this subsection from the application of all or any part of sections
589 195.010 to 195.320 if the compound, mixture, or preparation contains one or more
590 active medicinal ingredients not having a depressant effect on the central nervous
591 system, and if the admixtures are included therein in combinations, quantity,
592 proportion, or concentration that vitiate the potential for abuse of the substances
593 which have a depressant effect on the central nervous system.

594 9. The department of health and senior services shall place a substance
595 in Schedule V if it finds that:

596 (1) The substance has low potential for abuse relative to the controlled
597 substances listed in Schedule IV;

598 (2) The substance has currently accepted medical use in treatment in the
599 United States; and

600 (3) The substance has limited physical dependence or psychological
601 dependence liability relative to the controlled substances listed in Schedule IV.

602 10. The controlled substances listed in this subsection are included in
603 Schedule V:

604 (1) Any compound, mixture or preparation containing any of the following
605 narcotic drugs or their salts calculated as the free anhydrous base or alkaloid, in
606 limited quantities as set forth below, which also contains one or more nonnarcotic
607 active medicinal ingredients in sufficient proportion to confer upon the compound,
608 mixture or preparation valuable medicinal qualities other than those possessed
609 by the narcotic drug alone:

610 (a) Not more than two and five-tenths milligrams of diphenoxylate and not
611 less than twenty-five micrograms of atropine sulfate per dosage unit;

612 (b) Not more than one hundred milligrams of opium per one hundred
613 milliliters or per one hundred grams;

614 (c) Not more than five-tenths milligram of difenoxin and not less than
615 twenty-five micrograms of atropine sulfate per dosage unit;

616 (2) Any material, compound, mixture or preparation which contains any
617 quantity of the following substance having a stimulant effect on the central
618 nervous system including its salts, isomers and salts of isomers: pyrovalerone;

619 (3) Any compound, mixture, or preparation containing any detectable
620 quantity of pseudoephedrine or its salts or optical isomers, or salts of optical
621 isomers or any compound, mixture, or preparation containing any detectable
622 quantity of ephedrine or its salts or optical isomers, or salts of optical isomers;

623 (4) Unless specifically exempted or excluded or unless listed in another
624 schedule, any material, compound, mixture, or preparation which contains any
625 quantity of the following substances having a depressant effect on the central
626 nervous system, including its salts:

627 (a) Lacosamide;

628 (b) Pregabalin.

629 11. If any compound, mixture, or preparation as specified in subdivision
630 (3) of subsection 10 of this section is dispensed, sold, or distributed in a pharmacy
631 without a prescription:

632 (1) All packages of any compound, mixture, or preparation containing any
633 detectable quantity of pseudoephedrine, its salts or optical isomers, or salts of
634 optical isomers or ephedrine, its salts or optical isomers, or salts of optical
635 isomers, shall be offered for sale only from behind a pharmacy counter where the
636 public is not permitted, and only by a registered pharmacist or registered
637 pharmacy technician; and

638 (2) Any person purchasing, receiving or otherwise acquiring any
639 compound, mixture, or preparation containing any detectable quantity of
640 pseudoephedrine, its salts or optical isomers, or salts of optical isomers or
641 ephedrine, its salts or optical isomers, or salts of optical isomers shall be at least
642 eighteen years of age; and

643 (3) The pharmacist, intern pharmacist, or registered pharmacy technician
644 shall require any person, prior to their purchasing, receiving or otherwise
645 acquiring such compound, mixture, or preparation to furnish suitable photo
646 identification that is issued by a state or the federal government or a document
647 that, with respect to identification, is considered acceptable and showing the date
648 of birth of the person;

649 (4) The seller shall deliver the product directly into the custody of the
650 purchaser.

651 12. Pharmacists, intern pharmacists, and registered pharmacy technicians
652 shall implement and maintain an electronic log of each transaction. Such log
653 shall include the following information:

654 (1) The name, address, and signature of the purchaser;

655 (2) The amount of the compound, mixture, or preparation purchased;

656 (3) The date and time of each purchase; and

657 (4) The name or initials of the pharmacist, intern pharmacist, or
658 registered pharmacy technician who dispensed the compound, mixture, or
659 preparation to the purchaser.

660 13. Each pharmacy shall submit information regarding sales of any
661 compound, mixture, or preparation as specified in subdivision (3) of subsection 10
662 of this section in accordance with transmission methods and frequency
663 established by the department by regulation;

664 14. No person shall dispense, sell, purchase, receive, or otherwise acquire
665 quantities greater than those specified in this chapter.

666 15. All persons who dispense or offer for sale pseudoephedrine and
667 ephedrine products in a pharmacy shall ensure that all such products are located

668 only behind a pharmacy counter where the public is not permitted.

669 16. Any person who knowingly or recklessly violates the provisions of
670 subsections 11 to 15 of this section is guilty of a class A misdemeanor.

671 17. The scheduling of substances specified in subdivision (3) of subsection
672 10 of this section and subsections 11, 12, 14, and 15 of this section shall not apply
673 to any compounds, mixtures, or preparations that are in liquid or liquid-filled gel
674 capsule form or to any compound, mixture, or preparation specified in subdivision
675 (3) of subsection 10 of this section which must be dispensed, sold, or distributed
676 in a pharmacy pursuant to a prescription.

677 18. The manufacturer of a drug product or another interested party may
678 apply with the department of health and senior services for an exemption from
679 this section. The department of health and senior services may grant an
680 exemption by rule from this section if the department finds the drug product is
681 not used in the illegal manufacture of methamphetamine or other controlled or
682 dangerous substances. The department of health and senior services shall rely
683 on reports from law enforcement and law enforcement evidentiary laboratories in
684 determining if the proposed product can be used to manufacture illicit controlled
685 substances.

686 19. The department of health and senior services shall revise and
687 republish the schedules annually.

688 20. The department of health and senior services shall promulgate rules
689 under chapter 536 regarding the security and storage of Schedule V controlled
690 substances, as described in subdivision (3) of subsection 10 of this section, for
691 distributors as registered by the department of health and senior services.

692 21. Logs of transactions required to be kept and maintained by this
693 section and section 195.417 shall create a rebuttable presumption that the person
694 whose name appears in the logs is the person whose transactions are recorded in
695 the logs.

✓